Purpose DNX-2401 (Delta-24-RGD; tasadenoturev) is a tumor-selective, replication-competent oncolytic adenovirus. Preclinical studies demonstrated antiglioma efficacy, but the effects and mechanisms of action have not been evaluated in patients.
Methods
A phase I, dose-escalation, biologic-end-point clinical trial of DNX-2401 was conducted in 37 patients with recurrent malignant glioma. Patients received a single intratumoral injection of DNX-2401 into biopsy-confirmed recurrent tumor to evaluate safety and response across eight dose levels (group A). To investigate the mechanism of action, a second group of patients (group B) underwent intratumoral injection through a permanently implanted catheter, followed 14 days later by en bloc resection to acquire post-treatment specimens.
Results
In group A (n = 25), 20% of patients survived . 3 years from treatment, and three patients had a $ 95% reduction in the enhancing tumor (12%), with all three of these dramatic responses resulting in . 3 years of progression-free survival from the time of treatment. Analyses of post-treatment surgical specimens (group B, n = 12) showed that DNX-2401 replicates and spreads within the tumor, documenting direct virus-induced oncolysis in patients. In addition to radiographic signs of inflammation, histopathologic examination of immune markers in post-treatment specimens showed tumor infiltration by CD8 + and T-bet + cells, and transmembrane immunoglobulin mucin-3 downregulation after treatment. Analyses of patient-derived cell lines for damage-associated molecular patterns revealed induction of immunogenic cell death in tumor cells after DNX-2401 administration.
INTRODUCTION
Newly diagnosed glioblastoma (GBM) is treated with surgery, radiochemotherapy, and adjuvant chemotherapy, with a median survival time of approximately 15 months. [1] [2] [3] Despite maximal initial therapy, tumors invariably recur, after which the median survival time is typically only 6 months, even with reirradiation, repeat surgery, or chemotherapy. 1 Oncolytic adenoviruses are attractive therapeutic agents because they can kill tumor stem cells 4 and induce cell death by several mechanisms, including direct lysis, expression of toxic proteins, induction of cytokines, and T-cell-mediated immunity.
replication competent in tumor cells. 7, 8 To enhance potency, an RGD-motif was engineered into the fiber H-loop, enabling the virus to use a v b 3 or a v b 5 integrins to enter cells. 7 These integrins are typically enriched on tumor cells, including glioma stem cells. 4, 9, 10 In preclinical models, DNX-2401 kills glioma cells by direct oncolysis and by inducing immune responses against tumor antigens, leading to sustained antitumor immunity and tumor regression. 6, 7, 11 To determine safety, evaluate efficacy, and define the biologic effect of escalating doses of DNX-2401, we performed a phase I clinical trial with biologic end points in patients with recurrent malignant glioma. Remarkably, 20% of patients (five of 25) survived more than 3 years after a single DNX-2401 administration, and three of these five patients had . 95% reduction in tumor volumes that evolved over several months after treatment and that extended survival for . 3 years from the time of treatment. Biologic evaluations of post-treatment tumor specimens demonstrate that tumor regression induced by DNX-2401 seems to be due to the direct oncolytic effects of virus infection as well as activation of an immune-mediated antiglioma response.
METHODS

Study Design
A dose-escalation trial in patients with recurrent malignant glioma was conducted. Patients were enrolled in one of two groups (Fig 1A) . Group A (treatment-only group) underwent stereotactic biopsy to document recurrence, followed by a single intratumoral injection of DNX-2401 at the assigned dose through the biopsy needle into the contrastenhancing tumor mass. Group B (treat-resect-treat group) underwent stereotactic biopsy and intratumoral injection of DNX-2401 through an implanted catheter (to mark the injection site), followed 14 days later by craniotomy with en bloc tumor resection, including the catheter, and injection of a second dose of DNX-2401 into multiple sites in the wall of the resection cavity. This approach provided a post-treatment specimen in which the injection site was marked by the catheter. Dose escalation in group A used a 3 + 3 design, starting at 1 3 10 7 viral particles (vp; Data Supplement). Enrollment in group B lagged behind group A, opening only after safety of the dose level was established for intratumoral injection. The study was approved by the MD Anderson Institutional Review Board.
Patients and Study Treatment
Eligible patients were enrolled between 2009 and 2012, were older than 18 years of age with a Karnofsky performance scale score $ 70, and had histologically confirmed recurrent malignant glioma. Failure of standard or additional therapy was demonstrated by tumor progression as visualized on magnetic resonance imaging (MRI), and all patients underwent stereotactic biopsy before DNX-2401 administration (Data Supplement). DNX-2401 was manufactured at the Biopharmaceutical Development Program at SAIC-Frederick (Frederick, Maryland; Data Supplement).
Study Evaluations
Medical history, MRI, blood counts, and chemistry values were documented at screening and follow-ups (Data Supplement). Adverse events (AEs) were graded using Common Terminology Criteria for Adverse Events (version 3), and the relationship to DNX-2401 was assessed. Dose-limiting toxicity was defined as any DNX-2401-related, nonhematologic AE $ grade 3. Tumor response was based on Macdonald criteria, with the modification that (1) increases in tumor size (contrastenhancing volume) were allowed within the first 3 to 4 months to account for potential immune-mediated inflammatory responses as long as the patient was clinically stable, and (2) responses were judged as a complete response (CR) if there was $ 95% reduction in size of the enhancing tumor, a partial response if there was . 50% reduction, progressive disease if there was . 25% increase, and stable disease in all other situations. 12 
Biologic Assessments
Pretreatment biopsy specimens obtained before injection were stained with hematoxylin and eosin and evaluated by a certified neuropathologist to document recurrent tumor. Damage-associated molecular patterns were evaluated by enzymelinked immunosorbent assay in glioma sphere-forming cell (GSC) lines, GSC327 and GSC308, which were generated from fresh surgical tumor specimens 4 from patients in group B (Data Supplement). Serum, sputum, and urine were analyzed for the presence of adenovirus genomes using the polymerase chain reaction technique, as previously described 14 (Data Supplement). Serum was tested for antiadenovirus (type 5; anti-Ad5) by an indirect immunofluorescence assay before and at multiple times after treatment.
Statistics
Statistical justification is shown in the Data Supplement.
RESULTS
Demographics and Safety
Thirty-seven patients were enrolled in groups A (n = 25; Table 1 ) or B (n = 12) and received DNX-2401 according to the assigned regimen (Fig 1A) . Histology across both groups included GBM (89%), gliosarcoma (5%), or anaplastic astrocytoma (5%; Table 1 ). Median tumor diameter was 30 mm for group A and 41 mm for group B. Patients were enrolled at first (62%), second (32%), or third recurrence (5%) and had received a median of two prior treatment regimens. Three patients in group A (12%) were refractory to prior anti-vascular endothelial growth factor therapy.
In group A, eight dose-escalation cohorts were administered a single intratumoral dose of DNX-2401 into the contrastenhancing portion of the tumor (1 3 10 7 2 3 3 10 10 vp in 1 mL; Data Supplement). In group B, 11 patients underwent initial injection of DNX-2401 across four cohorts (1 3 10 7 2 3 3 10 8 vp) via an implanted catheter, and 14 days later underwent en bloc tumor resection and second injections into the wall of the resection cavity. One patient underwent surgical resection and injection of DNX-2401 into the residual tumor. Enrollment in group B was stopped at cohort 4 after assessment of post-treatment specimens indicated that the predefined biologic end point of viral replication had been achieved (see Viral Replication).
No dose-limiting toxicities were observed in the study; therefore, a maximum tolerated dose was not identified (Data jco.org Supplement), and 3 3 10 10 vp in 1 mL (cohort 8), the highest concentration of virus that could be manufactured, was deemed the maximal achieved dose. Only two patients experienced AEs related to DNX-2401, including grade 1 to 2 headache, nausea, confusion, vomiting, and pyrexia (Table 2 ). In one patient with a fever, adenoviral DNA was detected by the polymerase chain reaction method in serum and bone marrow; repeat testing was negative 4 months later (Data Supplement). Overall, adenoviral DNA was detected in , 3% of post-treatment serum, sputum, or urine samples and was not associated with AEs.
Viral Replication
The ability of DNX-2401 to replicate within human glioma was evaluated by assessing surgical specimens from patients in group B (n = 11). Tumor samples were cut perpendicular to the catheter, which marked the injection site ( Fig 1B) . Immunostaining revealed viral E1A or hexon protein in six of 11 tumors (55%), thus demonstrating virus replication in these tumors 14 days after treatment ( Fig 1C; Data Supplement). Expression of E1A or hexon coexisted with prominent inclusion bodies, characteristic of adenovirus replication ( Fig 1C, left and right) . The pattern of staining resembled the three zones of viral spread observed in animal models (zone 1: virus-induced necrosis; zone 2: active virus replication; zone 3: peripheral uninfected cells). 4, 7 These data demonstrate the ability of DNX-2401 to lyse glioma cells and provide evidence for active oncolytic adenovirus replication in human gliomas.
Efficacy
Tumor reductions were observed in 72% of patients (18 of 25) enrolled in group A (Fig 1D) , with a median overall survival time of 9.5 months regardless of dose. Most remarkably, five patients (20%) in group A survived for more than 3 years, three of whom had $ 95% reduction in a cross-sectional area of the enhancing tumor (designated as CRs; see Methods), and two patients had sustained stable disease after an initial tumor regression, all occurring at or above the 1 3 10 8 vp dose level (cohort 3; Fig 1E) . Importantly, all three of these dramatic ($ 95%) responses resulted in progression-free periods of $ 3 years from the time of treatment, attesting to the durability of the treatment effects of DNX-2401 (Fig 1E; Data Supplement) . Because of tumor resection on day 14, patients in group B were assessed only for survival; two patients (17%) survived for 2 years (Data Supplement), and the overall median survival time was 13.0 months across all cohorts.
Complete Responder No. 1 (Patient No. 12). A 53-year-old woman (Fig 2A) with a left parietal GBM underwent subtotal resection followed by radiation therapy and concurrent temozolomide plus dasatinib. One and one-half months after completing radiation therapy, MRI revealed progressive contrast enhancement at the site of the residual tumor that was present after the initial resection. Advanced brain imaging (including dynamic contrast enhancement MRI, dynamic susceptibility MRI, and magnetic resonance spectroscopy) was consistent with recurrent disease. The patient underwent stereotactic biopsy of the enhancing mass, documenting recurrent GBM (IDH1 wild type) and was treated with intratumoral injection of DNX-2401 (1 3 10 8 vp; cohort 3). MRI scans after virotherapy showed an initial decrease in contrastenhancing tumor, followed by increased enhancement that peaked of the injection catheter whose distal end extends into the center of the tumor and marks the site of DNX-2401 administration. After fixation, the en bloc specimen was blocked perpendicular to the catheter, and these blocks (right) were then sectioned and analyzed for viral replication; the arrows indicate the location of the catheter in each block, which allowed for precise identification of the site of DNX-2401 injection. (C) Photomicrographs of sections from en bloc resection specimens taken 14 days after virus injection showing immunohistochemical staining for viral E1A protein (left, 3100), which is a marker of viral infection, and for viral hexon protein (middle, 320; right, 340), which is a marker of replication. E1A immunostaining (left) is primarily intranuclear, as would be expected for actively infecting virus. after 4 months and then progressively decreased, to achieve dramatic regression (95% reduction) 17.6 months after treatment. From this point, serial MRI scans remained stable for 24.9 months, for a total progression-free period of 42.5 months (3.5 years) from initial treatment (Fig 2A) . At this time, an area of new enhancement appeared and progressed, requiring surgical resection that showed gliosarcoma. The patient died 14 months after the second recurrence (4.8 years after DNX-2401 treatment).
Complete responder No. 2 (Patient No. 33).
A 38-year-old woman, diagnosed with a GBM of her left superior temporal gyrus, underwent resection, followed by concurrent radiation therapy, temozolomide, and adjuvant isotretinoin (Fig 2B) . Three months after the completion of radiation therapy, progressive enhancement was identified, and advanced brain tumor imaging was consistent with recurrent tumor. The patient underwent stereotactic biopsy documenting recurrent GBM with active microvascular proliferation (IDH1 [R132H] and p53 [R248W] mutant) followed by intratumoral injection of DNX-2401 (1 3 10 10 vp; cohort 7). MRI scans 2 months after virotherapy showed an increase in the contrast enhancement before steady decreases and complete resolution (96% reduction) after 17.1 months, with the decrease in enhancement on T1-weighted images occurring concurrently with a decrease in peritumoral hyperintensity on fluid-attenuated inversion recovery images (Fig 2B) . From this point, serial MRI scans remained stable for 19.3 months, for a total progression-free period of 36.4 months (3.25 years) from the time of treatment, after which biopsy of a new enhancing lesion showed recurrent GBM. The patient died 23 months after recurrence (4.8 years after DNX-2401 treatment).
Complete responder No. 3 (Patient No. 37).
A 47-year-old man, diagnosed with a GBM of his right parietal lobe, underwent total resection, followed by concurrent radiation therapy and temozolomide treatment (Fig 2C) . He then received adjuvant temozolomide plus memantine. A new enhancing mass occurred 4 months after radiation therapy. The patient underwent stereotactic biopsy, documenting recurrent GBM with atypical cells and microvascular proliferation (IDH1 wild type), followed by intratumoral injection of DNX-2401 (3 3 10 10 vp; cohort 8). The patient resumed temozolomide treatment per his oncologist's preference. MRI initially showed an increase in tumor size that was followed by tumor regression until a complete response (100% reduction) was achieved after 12 months (Fig 2C) . Seventeen months after achieving a complete response, a new enhancing lesion was detected distant from the treated recurrence (Fig 2C) , and surgical resection of this lesion revealed only necrosis and no tumor cells. The patient remained stable for another 12 months until he experienced recurrence (ie, 29 months from the time of complete response and 41 months [3.4 years] from the treatment with DNX-2401). Resection of this recurrent mass revealed gliosarcoma. Despite repeated radiation therapy and chemotherapy, the recurrent tumor progressed, and 9 months after the second surgery, the patient was retreated with DNX-2401. He is currently alive 4.5 years after initial treatment with DNX-2401.
Immune Effects
In preclinical studies, DNX-2401 induces a T H 1-skewed CD8 + cytotoxic T-cell response. 11 Consistent with an immune-mediated response, contrast enhancement on MRI increased in all three complete responders from group A within 4 months after injection of DNX-2401, followed by a reduction in the size of the enhancing lesion over the next 12 to 18 months (Fig 2) . One patient with recurrent GBM of the left temporal lobe (Patient No. 20) underwent surgical resection 1.5 months after injection of DNX-2401 (3 3 10 8 vp) because of progressive symptoms. At this time, MRI showed necrosis at the injection site but increased contrast enhancement throughout the tumor (Fig 3A) . Analyses of the resected tumor revealed that 80% of the mass was necrotic, and the remaining specimen was largely acute with chronic inflammatory cell infiltration (macrophages and CD8 + T cells; Fig 3B) , without evidence of adenovirus-infected cells. Equally important, 2.5 years after treatment with DNX-2401, complete responder No. 3 (Patient No. 37) underwent resection for a new enhancing nodule distant from the initial lesion as described previously (Fig 2C, bottom right) . Pathologic examination revealed necrosis and inflammation, but no evidence of tumor, potentially indicative of an adaptive memory antitumor response.
Group B tumor specimens resected 14 days after DNX-2401 treatment (n = 9) were analyzed by immunohistochemistry for the presence of CD3, CD4, CD8, and T-bet (Fig 3C; Data Supplement) . CD3 + T cells were detected in all specimens either throughout the tumor or around the vessels (perivascular cuffing). The majority NOTE. Adverse events that were reported in at least 15% of the patients. Patients reporting a particular adverse event more than once are counted only once. Related events include those classified as possibly, probably, or definitely related to study drug. Laboratory abnormalities are not included; no studydrug-related events reported.
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were CD8 + , with lower representations of CD4 + cells. Lymphocytes were positive for T-bet, suggestive of a T H 1 response (Fig 3C) , as in preclinical experiments. 11 To quantify these results, we conducted an independent automated image analysis of immunohistochemically stained tumors 13 and determined cell density. For post-treatment specimens (n = 10), the mean density of CD3+, CD4+, and CD8+ cells was 119 6 217, 336 6 350, and 104 6 177 cells/mm 2 , respectively. Compared with five pretreatment specimens (three of five matched to post-treatment specimens), an increase in CD4 and CD8 cell density after treatment with DNX-2401 was observed, although jco.org statistically significant only for CD4 by this method (Fig 3D; P = .05 ). In addition, we performed a quantitative immunohistochemical analysis of the checkpoint proteins PD-1, PD-L1, IDO-1H, and TIM-3. A decrease in the expression of TIM-3 was evident when tumors (n = 10) after treatment with DNX-2401 were compared with tumors before treatment (n = 4; Fig 3E ; P = .06), without changes in the expression of PD-1, PD-L1, or IDO-1H (Data Supplement). Together, these data suggest that DNX-2401 is capable of increasing immune cell infiltrates in gliomas and can potentially alter checkpoint protein expression.
To evaluate immune-related signals, GSCs were isolated from the surgical specimens of two patients enrolled in group B, 15 treated with DNX-2401 in vitro, and assayed for immunogenic cell death. A significant increase in damage-associated molecular patterns 16 (high-mobility group proteins B1, heat-shock protein [HSP]90a, HSP70, ATP) was detected in GSCs after treatment, indicating that DNX-2401 induces immunogenic cell death (Fig 3F) .
Anti-Ad5 Titers
Anti-Ad5 antibodies were detected in low titers (1:8) before treatment in five of 25 patients (20%) in group A and none of 12 patients (0%) in group B (Data Supplement). Increases in anti-Ad5 titers were observed in 12 patients in group A and four patients in group B after treatment with DNX-2401. Two of the three patients with CR had an increase in anti-Ad5 titer.
DISCUSSION
In this dose-escalation study, we show that DNX-2401, a novel tumor-selective adenovirus, is safe and capable of robust viral replication and killing of recurrent high-grade glioma cells. Secondary antiglioma immune-mediated responses were observed. Importantly, these biologic mechanisms translated into clinical benefit, including three dramatic responses ($ 95% reduction in tumor size) with long progression-free intervals and long-term survival after treatment with DNX-2401. To our knowledge, this is the first clinical study to show direct oncolysis and replication of a therapeutic adenovirus in human brain tumors and to provide correlative evidence for a viral-induced antiglioma immune response.
By marking the injection with a catheter, we were able to localize the site of virus injection and assess viral replication. DNX-2401 infection, replication, and killing followed the three-concentric-zone pattern that we described in preclinical animal models (Fig 1C) . 4, 7 However, not all patients in group B showed evidence of infection, possibly because of inefficient delivery, inadequate infection/replication, or rapid immune-mediated elimination. To standardize delivery, current clinical studies are focused on assessing purpose-built cannulas to deliver DNX-2401. [17] [18] [19] [20] Although viral replication was evident in posttreatment specimens collected 2 weeks after treatment, specimens taken beyond 1 month did not show evidence of virus, suggesting that DNX-2401 does not persist long term or falls below the detection limit over time, consistent with observations in immunocompetent animal models. 11 However, clinical responses ($ 95% reduction in tumor size)
were typically first evident at more than 3 months after treatment, pointing to a robust secondary antitumor immune effect. Immune responses were observed after a single injection of DNX-2401 into human glioma. Widespread necrosis with infiltration of T cells, consistent with a T H 1 immune response, was observed in surgical specimens obtained 14 days after DNX-2401 treatment, as in preclinical studies, 11, 21 and in surgical specimens obtained at the time of increased tumor enhancement seen on MRI. Examination of a recurrent enhancing nodule located away from the originally injected tumor 2.5 years after a complete response to DNX-2401 ( Fig 2C) revealed only inflammation without evidence of tumor, suggestive of an adaptive immune memory effect. In all three patients with a reduction of $ 95% in tumor size (ie, CRs), tumor regression occurred over a 1-to 1.5-year period, and the pattern of tumor enhancement on MRI was reminiscent of pseudo-progression (ie, therapy-mediated tumor enhancement), which is considered a radiographic hallmark of inflammation and is observed with immune checkpoint inhibitors. [22] [23] [24] One of the mechanisms of tumor immune suppression is T-cell exhaustion. 25 Combinations of inhibitory receptors such as PD-1 and TIM-3 coregulate exhausted T cells 26 and cooperate to induce deficiency of CD8 + T cells. 27, 28 Here, although PD-1 was not significantly modified after DNX-2401 treatment, tumor infection induced a decrease in TIM-3 expression (Fig 3E) , indicating that DNX-2401 may partially overcome some features of T-cell exhaustion and suggesting that combining DNX-2401 with checkpointbased therapies may further augment clinical benefit. The combination of DNX-2401 and anti-PD-1 antibodies is currently being evaluated (ClinicalTrials.gov identifier: NCT02798406). In all, these results provide the first clinical correlates that DNX-2401 can induce a direct oncolytic effect followed by an antitumor immune response. Insofar as DNX-2401 is highly efficient because of expanded infectivity conferred by the RGD motif, and insofar as it is capable of enhancing antigen presentation, 11 we speculate that these effects lead to immune cell infiltration and antitumor activity.
shows complete removal of the mass (far right). (B) The pathologic examination of the tumor resected in Figure 3A , including hematoxylin and eosin-stained section (far left) demonstrating large numbers of small hematoxylin-stained inflammatory cells around blood vessels. Immunostaining shows infiltration of macrophages (CD68; second from left), T cells (CD-3; middle), few CD4+ T cells (second from right), and large numbers of CD8+ T cells (far right), all consistent with a cytotoxic immune response. The patient died of a pulmonary embolism 1.5 months after the surgery; therefore, his outcome related to the tumor could not be assessed. (C) Representative cases of post-treated specimens from patients from group B taken 14 days after treatment with DNX-2401 and immunostained for macrophages (CD68), T cells (CD3), cytotoxic T cells (CD8), and T-bet+ T cells; note the prominent perivascular cuffing of all these cell types. Each dot represents a different patient. Different colors and shapes were used in the plotted points because many overlapped. The CD8 and T-bet specimens are serial sections from the same patient. T-bet expression correlated with increased CD8+ T cells as expected of a TH1 immune response (far right).
Graphs showing the density of (D) CD3+, CD4+, and CD8+ cells and (E) TIM-3+ cells on the basis of quantitative analyses of pretreatment (pre; n = 5) and post-treatment (post; n = 10) tumor specimens. Post-treatment specimens were from patients in group B treated with DNX-2401 14 days previously, and five pretreatment specimens were the matched pretreatment biopsies of three patients in group B and two unmatched specimens (one from group B and one from group A). The mean values are noted by horizontal bars; although CD3+ changes were not evident, both CD4+ and CD8+ cells increased after treatment, with increases in CD4+ cells reaching statistical significance. A decrease in the exhaustion marker TIM-3 was seen after treatment with DNX-2401. (F) Graphs showing analyses of damage-associated molecular patterns (DAMPs) in glioma stem cells cultured from the surgical specimens of two patients enrolled in group B. Glioma sphere-forming cells (GSC) 327 and GSC308 were cultured and treated with either mock infection (blue bars) or with DNX-2401 (dose of 20 active viral particles per cell; gold bars). After 72 hours, the supernatant was collected and analyzed by enzyme-linked immunosorbent assay for the following damage-associated molecular patterns: high-mobility group proteins B1 (HMGB1), heat-shock protein (HSP)90a, HSP70, and ATP. Data represent mean 6 standard deviation. *P # .05; ***P # .001.
(Continued)
DNX-2401 warrants further study as a single agent and in combination with other immune-modulatory therapeutics.
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